Last night, OPM announced a partnership with German ‘Navigo Proteins' for the development of radiotherapeutic drug candidates focused on two oncology targets. OPM will fund the program over the next three years. No financial details disclosed.Navigo's precision targeting technology is based on so-called Affilins®, small proteins derived from human ubiquitin, which offer several benefits over traditional antibodies in radiotheranostic development.Promising partnership for OPM which supports the c ....
